World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
112
Citations
86182
World Ranking
5040
National Ranking
101

Overview

Jonas Bergh is affiliated with the Karolinska Institute in Sweden and has contributed extensively to the fields of medicine, particularly focusing on oncology and cancer research. Their scholarly work spans multiple disciplines such as biochemistry, genetics, and molecular biology, with a significant emphasis on cancer treatment studies and diagnostics.

Their research output demonstrates engagement with key subfields including oncology, cancer research, pulmonary and respiratory medicine, radiology, nuclear medicine, imaging, and molecular biology. Jonas Bergh's work frequently addresses topics such as breast cancer treatment studies, HER2/EGFR in cancer research, advanced breast cancer therapies, cancer treatment and pharmacology, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, and the application of radiomics and machine learning in medical imaging.

Jonas Bergh has published numerous papers in prominent scientific journals. Selected recent publications include:

  • Pembrolizumab for Early Triple-Negative Breast Cancer, 2020, New England Journal of Medicine
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), 2020, Annals of Oncology
  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021, 2021, Annals of Oncology
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology
  • Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, 2022, Annals of Oncology

The venues most frequently publishing Jonas Bergh's work include:

  • ESMO Open
  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research

Collaboration has been an important aspect of their research endeavors. Frequent co-authors include Theodoros Foukakis, Alexios Matikas, Ioannis Zerdes, Johan Hartman, and Emmanouil G. Sifakis.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

    Christos Sotiriou;Pratyaksha Wirapati;Sherene Loi;Adrian Harris

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

    R Peto;C Davies;J Godwin

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

    Lance D. Miller;Johanna Smeds;Joshy George;Vinsensius B. Vega

  • Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

    Marc Buyse;Sherene Loi;Laura van't Veer;Giuseppe Viale

  • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

    Hongchao Pan;Richard Gray;Jeremy Braybrooke;Christina Davies

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,

    Christine Desmedt;Fanny Piette;Sherene Loi;Yixin Wang

  • Identification of molecular apocrine breast tumours by microarray analysis

    Pierre Farmer;Herve Bonnefoi;Véronique Becette;Michele Tubiana-Hulin

  • Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

    Sherene Loi;Benjamin Haibe-Kains;Christine Desmedt;Françoise Lallemand

  • Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

    Yudi Pawitan;Judith Bjöhle;Lukas Amler;Anna-Lena Borg

  • Identification of molecular apocrine breast tumours by microarray analysis

    P Farmer;H Bonnefoi;V Becette;M Tubiana-Hulin

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer

    Anna V. Ivshina;Joshy George;Oleg Senko;Benjamin Mow

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

Frequent Co-Authors

Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Peter Nygren
Peter Nygren Uppsala University
Per Hall
Per Hall Karolinska Institute
Kamila Czene
Kamila Czene Karolinska Institute
Michael Gnant
Michael Gnant Medical University of Vienna
Martine Piccart
Martine Piccart Université Libre de Bruxelles
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Mauro Delorenzi
Mauro Delorenzi University of Lausanne
Kenneth Nilsson
Kenneth Nilsson Uppsala University
Carl Blomqvist
Carl Blomqvist University of Helsinki

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in Medicine doesn’t always mean following the traditional path to becoming a doctor. There are multiple related fields and online degree options that lead to high-demand roles in healthcare. For example, if you are interested in medication therapy, you might consider earning an online pharmacist degree. This degree prepares you for a variety of pharmacy roles in hospitals, clinics, and community settings.

For those drawn to the organizational and technical side of healthcare, HIM programs focus on managing electronic health records and ensuring data security, while medical billing and coding classes online offer a fast entry into administrative roles that keep clinics and hospitals running efficiently.

If patient care is your passion, but medical school isn’t the right fit, consider cheap np programs which can help you become a nurse practitioner and deliver advanced care in many settings. Each of these online degree options opens distinct career pathways within healthcare, offering flexibility and affordability for future professionals.

Best Scientists Citing Jonas Bergh

Trending Scientists